Table 2.

Final multivariate logistic regression model (polytomous) of HPV cofactors among women enrolled in SUCCEED restricted to women infected with any HPV type, oncogenic HPV types, HPV16 only, HPV16 or HPV18, or oncogenic HPV types excluding HPV16 and HPV18

CharacteristicsCIN3 vs <CIN2
CIN2 vs <CIN2
All HPV
Oncogenic HPV
HPV16
HPV16 or 18
Oncogenic Non-HPV16, HPV18
All HPV
Oncogenic HPV
HPV16
HPV16 or HPV18
Oncogenic Non-HPV16, HPV18
OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)
Race
    White1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    Black0.6 (0.3-1.0)0.7 (0.4-1.1)0.9 (0.4-2.1)1.0 (0.4-2.1)0.9 (0.4-2.1)0.8 (0.5-1.2)0.9 (0.6-1.3)1.5 (0.7-3.1)1.6 (0.8-3.1)0.7 (0.4-1.3)
    Other0.9 (0.5-1.5)0.9 (0.6-1.6)1.1 (0.5-2.4)1.1 (0.5-2.2)0.7 (0.2-2.3)1.1 (0.7-1.8)1.2 (0.7-1.8)1.2 (0.5-2.7)1.0 (0.5-2.2)1.4 (0.7-2.6)
Income ($)
    <10,0001.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    10,001-40,0001.2 (0.9-1.7)1.3 (0.9-1.8)1.6 (1.0-2.6)1.5 (1.0-2.4)1.0 (0.6-2.0)1.2 (0.9-1.6)1.2 (0.9-1.7)1.9 (1.1-3.0)1.6 (1.0-2.4)0.9 (0.6-1.4)
    ≥40,0001.9 (1.0-3.6)2.0 (1.0-3.8)2.4 (0.9-6.5)2.0 (0.8-4.9)3.9 (1.2-12.6)1.3 (0.7-2.4)1.3 (0.7-2.5)2.6 (1.0-7.2)2.3 (0.9-5.7)0.8 (0.3-2.1)
Lifetime no. sexual partners
    11.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    2-31.1 (0.6-2.3)1.1 (0.5-2.3)2.9 (0.9-9.2)2.2 (0.7-6.3)0.3 (0.1-1.0)1.6 (0.9-2.9)1.5 (0.8-2.9)2.2 (0.7-6.7)1.9 (0.7-5.3)1.2 (0.5-2.8)
    4-101.4 (0.7-2.7)1.3 (0.7-2.6)2.6 (0.9-7.8)1.9 (0.7-5.4)0.6 (0.2-1.7)1.5 (0.8-2.7)1.4 (0.8-2.7)1.9 (0.7-5.6)1.6 (0.6-4.3)1.1 (0.5-2.7)
    ≥111.4 (0.7-2.8)1.4 (0.6-2.9)2.8 (0.8-8.9)1.7 (0.6-5.1)0.7 (0.2-2.2)1.2 (0.6-2.3)1.1 (0.5-2.2)1.2 (0.4-3.9)0.9 (0.3-2.6)1.2 (0.5-3.1)
No. pregnancies
    01.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    1-31.6 (1.1-2.3)1.5 (1.0-2.3)1.2 (0.7-2.1)1.2 (0.7-1.9)3.2 (1.2-8.4)1.0 (0.8-1.4)1.0 (0.7-1.3)0.7 (0.4-1.3)0.8 (0.5-1.3)1.1 (0.7-1.9)
    ≥42.1 (1.3-3.6)2.0 (1.2-3.3)1.7 (0.8-3.6)1.7 (0.9-3.4)3.3 (1.1-10.2)1.1 (0.7-1.8)0.9 (0.5-1.5)0.7 (0.3-1.6)0.7 (0.3-1.5)1.3 (0.6-2.7)
Smoking
    Never1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    Current2.5 (1.8-3.6)2.5 (1.8-3.6)2.7 (1.6-4.6)2.9 (1.8-4.7)2.0 (1.0-3.8)1.3 (0.9-1.7)1.3 (0.9-1.8)1.9 (1.1-3.2)1.7 (1.1-2.8)1.0 (0.6-1.5)
    Former1.4 (0.9-2.3)1.5 (0.9-2.4)1.6 (0.8-3.2)1.8 (0.9-3.4)1.4 (0.6-3.4)0.8 (0.5-1.2)0.8 (0.5-1.3)0.8 (0.3-1.8)0.9 (0.4-1.9)0.8 (0.4-1.4)
Oral contraceptive use
    Never1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    Ever1.1 (0.7-1.6)1.1 (0.7-1.7)0.9 (0.5-1.7)1.0 (0.6-1.8)2.0 (0.7-6.1)1.0 (0.7-1.5)1.1 (0.7-1.6)1.4 (0.7-2.8)1.7 (0.9-3.2)0.7 (0.4-1.3)
BMI
    20 to <251.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)1.0 (Reference)
    25 to <301.4 (0.9-2.0)1.4 (0.9-2.1)1.5 (0.9-2.7)1.5 (0.9-2.4)1.7 (0.8-3.5)0.9 (0.6-1.2)0.8 (0.6-1.2)1.0 (0.6-1.8)1.1 (0.7-1.8)0.6 (0.4-1.1)
    ≥301.5 (1.0-2.2)1.6 (1.1-2.3)1.6 (0.9-2.7)1.5 (0.9-2.6)2.0 (1.0-4.2)0.8 (0.6-1.1)0.8 (0.6-1.2)0.7 (0.4-1.4)0.8 (0.5-1.4)0.7 (0.4-1.2)
    <202.0 (1.3-3.1)2.0 (1.3-3.2)2.3 (1.2-4.3)2.5 (1.4-4.6)1.3 (0.5-3.7)1.1 (0.7-1.7)1.2 (0.8-1.8)1.2 (0.6-2.3)1.4 (0.8-2.7)0.9 (0.5-1.8)
  • NOTE: Final models include all variables listed and age (quintiles) for comparisons of CIN3 compared with <CIN2 and CIN2 compared with <CIN2.